Proteins aggregate in several slowly progressive neurodegenerative diseases called ‘proteinopathies’. Studies with cell cultures and transgenic mice overexpressing mutated proteins suggested that aggregates of one protein induced misfolding and aggregation of other proteins as well – a possible common mechanism for some neurodegenerative diseases. However, most proteinopathies are ‘sporadic’, without gene mutation or overexpression. Thus, proteinopathies in WT animals genetically close to humans might be informative. Squirrel monkeys infected with the classical bovine spongiform encephalopathy agent developed an encephalopathy resembling variant Creutzfeldt–Jakob disease with accumulations not only of abnormal prion protein (PrPTSE), but also three other proteins: hyperphosphorylated tau (p-tau), α-synuclein and ubiquitin; β-amyloid protein (Aβ) did not accumulate. Severity of brain lesions correlated with spongiform degeneration. No amyloid was detected. These results suggested that PrPTSEenhanced formation of p-tau and aggregation of α-synuclein and ubiquitin, but not Aβ, providing a new experimental model for neurodegenerative diseases associated with complex proteinopathies.
Incubation periods in humans infected with transmissible spongiform encephalopathy (TSE) agents can exceed 50 years. In humans infected with bovine spongiform encephalopathy (BSE) agents, the effects of a “species barrier,” often observed when TSE infections are transmitted from one species to another, would be expected to increase incubation periods compared with transmissions of same infectious agents within the same species. As part of a long-term study investigating the susceptibility to BSE of cell cultures used to produce vaccines, we inoculated squirrel monkeys (Saimiri sp., here designated SQ) with serial dilutions of a bovine brain suspension containing the BSE agent and monitored them for as long as ten years. Previously, we showed that SQ infected with the original “classical” BSE agent (SQ-BSE) developed a neurological disease resembling that seen in humans with variant CJD (vCJD). Here, we report the final characterization of the SQ-BSE model. We observed an unexpectedly marked difference in incubation times between two animals inoculated with the same dilution and volume of the same C-BSE bovine brain extract on the same day. SQ-BSE developed, in addition to spongiform changes and astrogliosis typical of TSEs, a complex proteinopathy with severe accumulations of protease-resistant prion protein (PrPTSE), hyperphosphorylated tau (p-tau), ubiquitin, and α-synuclein, but without any amyloid plaques or β-amyloid protein (Aβ) typical of Alzheimer’s disease. These results suggest that PrPTSE enhanced the accumulation of several key proteins characteristically seen in human neurodegenerative diseases. The marked variation in incubation periods in the same experimental TSE should be taken into account when modeling the epidemiology of human TSEs.
Background: Transmissible spongiform encephalopathy (TSE) agents are lethal unconventional pathogens that have infected both humans and animals. Bovine spongiform encephalopathy (BSE) is a TSE. TSE agents are unusually resistant to inactivation. In-use tests conducted to investigate decontamination products involve intentionally contaminating carrier objects with TSE agents, exposing them to decontaminating regimens, and then surgically implanting treated carriers into TSE-susceptible rodents to assay for TSE infectivity. Objective: To adapt a simple in-use carrier test to decontaminate TSE agents based on methods employed for decades to test for bacteria, fungi, and viruses remaining on surfaces treated with disinfectants, known as “use-dilution tests.” Methods: We serially diluted 10% BSE brain homogenate in a normal bovine-brain-tissue paste and contaminated 60 stainless-steel pins mounted in disposable heat-resistant plastic holders with the lowest dilution and five or six pins with each successive dilution. We investigated 2 N NaOH—known to inactivate TSE agents—with and without autoclaving (121°C and 134°C) and autoclaving without exposure to NaOH. Each pin was briefly introduced into the brain of an anesthetized mouse. We monitored animals for 24 months. At the end of the study, the brains of all mice (except six mice that died early post-inoculation) were tested for the presence of abnormal prion protein, a marker of TSE infections. Next, we calculated the level of inactivation provided by each method. Results: Our results indicated that none of the 60 animals inoculated with pins decontaminated with NaOH (with or without autoclaving) developed BSE, while steam autoclaving alone at both conventional and elevated temperatures was not effective. This inactivation corresponded to ≥1.1 log10 reduction of infectivity. Conclusions: Using our relatively simple and quick pin method with brief intracerebral punctures without surgical implantation, we tested many more replicate treated carriers than in studies previously reported while yielding similar results. Highlights: The proposed pin method was proven effective to evaluate inactivation regimens for BSE agents.